PharmaMar Archives -

The pipeline for dry eye disease drugs is beginning to heat up, with two biotechs announcing key developments,

Two biotechs target dry eye disease after Novartis’ Xiidra problems

https://pharmaphorum.com/news/two-biotechs/

Boehringer Ingelheim has moved a step closer to getting approval for its blockbuster respiratory drug Ofev as the

Boehringer bags CHMP backing for Ofev in rare lung disease

https://pharmaphorum.com/news/boehringer-bags-chmp-backing-for-ofev-in-rare-lung-disease/

PharmaMar and Jazz Pharmaceuticals have announced the FDA has granted a six-month Priority Review for their lurbinectedin for

Jazz targets US launch of SCLC drug after FDA grants fast review

https://pharmaphorum.com/news/jazz-targets-us-launch-of-sclc-drug-after-fda-grants-fast-review/

Spain’s PharmaMar and Jazz Pharmaceuticals have signed a $1 billion license agreement for the lung cancer drug lurbinectedin

PharmaMar and Jazz sign $1bn US deal for lung cancer drug lurbinectedin

https://pharmaphorum.com/news/pharmamar-and-jazz-sign-1bn-us-deal-for-lung-cancer-drug/

PharmaMar